During the past decade, Hanna Cancer Associates - University of Tennessee conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hanna Cancer Associates - University of Tennessee" are "Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Hanna Cancer Associates - University of Tennessee" in a lesser frequency.

Most popular intervention types in "Hanna Cancer Associates - University of Tennessee" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Trilaciclib" (2 trials), "Carboplatin" (1 trials), "Etoposide" (1 trials) and "Topotecan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hanna Cancer Associates - University of Tennessee" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hanna Cancer Associates - University of Tennessee". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Hanna Cancer Associates - University of Tennessee, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hanna Cancer Associates - University of Tennessee, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".